Wegovy, the weight-loss drug currently administered by weekly injection, is set to become available in oral tablet form in the UK for the first time, according to a BBC News report.
A Shift From Injection to Tablet
The existing formulation of Wegovy requires a subcutaneous injection once per week. The newly announced tablet format would instead be taken daily. Novo Nordisk, the drug's manufacturer, has indicated that a daily oral dose may represent a more convenient option for certain individuals compared with the current injectable regimen.
Potential Implications for Access
The introduction of a pill format could broaden the drug's appeal, particularly among those who are reluctant to use injectable medications. Oral administration is generally considered more familiar and straightforward for many people, which may influence uptake if the tablet becomes widely available through existing prescribing channels in the UK.
The BBC reported that Novo Nordisk positioned the tablet as an alternative rather than a replacement, suggesting both formats may remain available. No specific timeline for full availability was detailed in the report.
Context Around Wegovy
Wegovy has attracted considerable attention in recent years as part of a broader class of weight-management treatments. The injectable version has been prescribed in the UK following regulatory approval, though supply constraints have at times affected availability. Whether the oral formulation faces similar logistical challenges has not yet been reported.
The development reflects a wider trend among pharmaceutical manufacturers toward offering alternative delivery methods for established treatments, with the aim of reducing barriers associated with self-injection.